Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateWages, Salaries and Other
Others
Ratios

VitaNova Life Sciences (YJGJ) Income from Continuing Operations (2017 - 2026)

VitaNova Life Sciences (YJGJ) has disclosed Income from Continuing Operations for 9 consecutive years, with 35810.0 as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Income from Continuing Operations rose 9.69% year-over-year to 35810.0, compared with a TTM value of 862819.0 through Oct 2025, up 470.26%, and an annual FY2025 reading of 850746.0, up 503.94% over the prior year.
  • Income from Continuing Operations was 35810.0 for Q4 2025 at VitaNova Life Sciences, up from 46301.0 in the prior quarter.
  • Across five years, Income from Continuing Operations topped out at 800332.0 in Q2 2025 and bottomed at 55211.0 in Q3 2024.
  • Average Income from Continuing Operations over 5 years is 53405.65, with a median of 2367.5 recorded in 2022.
  • The sharpest move saw Income from Continuing Operations plummeted 1236.22% in 2023, then soared 3929.4% in 2024.
  • Year by year, Income from Continuing Operations stood at 15009.0 in 2021, then crashed by 82.67% to 2601.0 in 2022, then tumbled by 436.6% to 8755.0 in 2023, then surged by 472.9% to 32647.0 in 2024, then rose by 9.69% to 35810.0 in 2025.
  • Business Quant data shows Income from Continuing Operations for YJGJ at 35810.0 in Q4 2025, 46301.0 in Q3 2025, and 800332.0 in Q2 2025.